Hummingbird Diagnostics GmbH news

• Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic
• Results published in Journal of Thoracic Oncology Clinical and Research Reports

Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology Clinical and Research Report

• Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy.
• Blood-based test holds potential for broad applicability for the management of patients with cancer.

Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal n

• Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias
• Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects
• ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos and MacKenzie Bezos, the Dolby family, the Charles and